Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

AKYA

Akoya Biosciences Inc

May 10 • 04:00PM ET

4.26

Dollar change -0.22
Percentage change -4.80	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO SCHA VTWO VHT IWC VTWG SCHB

Index	RUT	P/E	-	EPS (ttm)	-1.49	Insider Own	56.63%	Shs Outstand	49.12M	Perf Week	5.57%
Market Cap	210.61M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-0.13%	Shs Float	21.91M	Perf Month	-0.81%
Income	-63.32M	PEG	-	EPS next Q	-0.29	Inst Own	29.62%	Short Float	4.73%	Perf Quarter	-29.62%
Sales	96.63M	P/S	2.18	EPS this Y	41.35%	Inst Trans	3.88%	Short Ratio	6.31	Perf Half Y	13.43%
Book/sh	1.09	P/B	3.90	EPS next Y	37.54%	ROA	-35.53%	Short Interest	1.04M	Perf Year	-35.18%
Cash/sh	1.68	P/C	2.53	EPS next 5Y	-	ROE	-112.72%	52W Range	3.04 - 8.80	Perf YTD	-12.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-37.60%	ROI	-46.55%	52W High	-51.53%	Beta	1.57
Dividend TTM	-	Quick Ratio	2.94	Sales past 5Y	23.82%	Gross Margin	49.92%	52W Low	40.30%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	3.45	EPS Y/Y TTM	20.57%	Oper. Margin	-57.98%	RSI (14)	53.55	Volatility	8.42% 5.87%
Employees	330	Debt/Eq	1.59	Sales Y/Y TTM	29.09%	Profit Margin	-65.53%	Recom	1.38	Target Price	9.00
Option/Short	Yes / Yes	LT Debt/Eq	1.53	EPS Q/Q	55.71%	Payout	-	Rel Volume	0.95	Prev Close	4.48
Sales Surprise	1.34%	EPS Surprise	18.15%	Sales Q/Q	24.83%	Earnings	May 13 AMC	Avg Volume	164.26K	Price	4.26
SMA20	7.59%	SMA50	-4.82%	SMA200	-9.93%	Trades		Volume	155,730	Change	-4.80%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Guggenheim	Neutral
Jul-05-23	Resumed	JP Morgan	Overweight	$18
Feb-02-23	Initiated	UBS	Buy	$14
Nov-03-22	Initiated	CapitalOne	Overweight	$19
Oct-06-22	Initiated	Stephens	Overweight	$16
Jun-22-22	Initiated	BTIG Research	Buy	$16
Jan-06-22	Resumed	Piper Sandler	Overweight	$23
May-11-21	Initiated	Piper Sandler	Overweight	$28
May-11-21	Initiated	Morgan Stanley	Overweight	$26
May-11-21	Initiated	JP Morgan	Overweight	$23
May-11-21	Initiated	Canaccord Genuity	Buy	$25

Show Previous Ratings

May-09-24 08:00AM	Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients (GlobeNewswire) +9.00%
May-06-24 10:00AM	Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
08:00AM	Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts (GlobeNewswire)
May-02-24 08:00AM	Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows (GlobeNewswire)
Apr-22-24 04:05PM	Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024 (GlobeNewswire)
08:00AM	Loading…
Apr-05-24 08:00AM	Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale (GlobeNewswire)
Mar-05-24 09:52AM	Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Call Transcript (Insider Monkey) -14.72%
07:00AM	Q4 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 08:51PM	AKYA Stock Earnings: Akoya Biosciences Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:31PM	Akoya Biosciences Inc (AKYA) Reports Record Q4 Revenue and Sets Positive 2024 Outlook (GuruFocus.com)
05:15PM	Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Akoya: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook (GlobeNewswire)
Feb-08-24 04:05PM	Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference (GlobeNewswire)
Feb-07-24 04:13AM	Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength? (Zacks)
08:00AM	Loading…
Jan-18-24 08:00AM	Akoya Biosciences' Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases (GlobeNewswire)
Jan-10-24 08:00AM	Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board (GlobeNewswire)
Jan-08-24 01:07AM	Akoya Biosciences Issues Preliminary Revenue Results; Issues 2024 Guidance (RTT News) +20.09%
Jan-07-24 08:00AM	Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform (GlobeNewswire)
08:00AM	Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook (GlobeNewswire)
08:00AM	Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow (GlobeNewswire)
Jan-05-24 08:34AM	How Akoya Biosciences (AKYA) Stock Stands Out in a Strong Industry (Zacks)
Dec-27-23 09:55AM	How Much Upside is Left in Akoya (AKYA)? Wall Street Analysts Think 86% (Zacks)
Dec-20-23 08:05AM	Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-12-23 10:51AM	Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 10:25AM	Q3 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +10.90%
Nov-08-23 05:51PM	Akoya Biosciences Inc (AKYA) Reports 34% Year-Over-Year Revenue Growth in Q3 2023 (GuruFocus.com)
04:05PM	Akoya: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-02-23 08:00AM	Akoya to Participate at Three Upcoming Investor Conferences (GlobeNewswire) +7.92%
10:01AM	Loading…
Nov-01-23 10:01AM	Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-31-23 09:00AM	Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023 (GlobeNewswire)
Oct-17-23 10:22AM	Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures (GlobeNewswire) +5.41%
Oct-11-23 04:05PM	Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023 (GlobeNewswire) -8.21%
Sep-19-23 08:00AM	Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-08-23 12:38PM	Q2 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 06:15PM	Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:02PM	Akoya: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
08:05AM	Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies (GlobeNewswire)
Aug-06-23 10:57AM	Private equity firms account for 49% of Akoya Biosciences, Inc.'s (NASDAQ:AKYA) ownership, while institutions account for 29% (Simply Wall St.)
Jul-26-23 04:05PM	Akoya to Participate at Three Upcoming Investor Conferences (GlobeNewswire)
Jul-21-23 09:21AM	Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod (Zacks)
Jul-12-23 09:55AM	Can Akoya (AKYA) Climb 116.14% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:05AM	Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023 (GlobeNewswire)
Jul-10-23 10:08AM	The past year for Akoya Biosciences (NASDAQ:AKYA) investors has not been profitable (Simply Wall St.) +5.47%
Jun-13-23 07:58PM	Insiders Pour Millions Into These 2 Stocks, J.P. Morgan Says They Have up to 175% Upside Heres Why You Should Pay Attention (TipRanks) +20.40%
12:32PM	Why Shares of Akoya Biosciences Jumped on Tuesday (Motley Fool)
08:29AM	Independent Director of Akoya Biosciences Picks Up 26% More Stock \ (Simply Wall St.)
06:37AM	Daily Vickers Top Buyers & Sellers for 06/13/2023 (Argus Research)
Jun-12-23 04:05PM	Akoya to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Jun-08-23 12:55AM	Akoya Biosciences Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -5.04%
Jun-07-23 04:08PM	Akoya Biosciences Announces Public Offering of Common Stock (GlobeNewswire)
May-09-23 10:43AM	Q1 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:35PM	Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.99%
04:32PM	Akoya: Q1 Earnings Snapshot (AP Finance)
04:05PM	Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
May-05-23 07:36AM	Is Akoya Biosciences, Inc. (NASDAQ:AKYA) Trading At A 34% Discount? (Simply Wall St.)
Apr-27-23 08:00AM	Akoya Biosciences Marks Milestone Achievement with Shipment of 1,000th Spatial Biology Instrument (GlobeNewswire)
Apr-17-23 12:20PM	A Piece Of The Puzzle Missing From Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Share Price (Simply Wall St.) +6.53%
Apr-14-23 03:38PM	Down More Than 50%: These 2 Strong Buy Stocks Are Flirting With a Bottom (TipRanks)
Apr-12-23 08:00AM	Akoya Biosciences Introduces PhenoCode Discovery Panels to Simplify PhenoCycler-Fusion Workflow (GlobeNewswire) -6.48%
08:00AM	Akoya Biosciences and Enable Medicine Introduce Cloud Platform to Power Faster Analysis of PhenoCycler-Fusion Data (GlobeNewswire)
Apr-06-23 08:00AM	Akoya to Report First Quarter 2023 Financial Results on May 8th, 2023 (GlobeNewswire)
Mar-20-23 04:00PM	Akoya Biosciences Announces Leadership Transition (GlobeNewswire) -5.47%
Mar-09-23 05:17AM	Akoya Biosciences Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Mar-08-23 07:21AM	Akoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 09:52AM	Q4 2022 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 05:35PM	Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.11%
04:05PM	Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance (GlobeNewswire)
Feb-28-23 08:00AM	Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel (GlobeNewswire) -5.41%
Feb-27-23 10:00AM	Will Akoya Biosciences (AKYA) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-10-23 06:36PM	Argo Group and Akoya Biosciences Stock See Action From Activist Investors (Barrons.com)
Feb-06-23 08:05AM	Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Feb-01-23 08:00AM	Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting (GlobeNewswire)
Jan-08-23 04:00PM	Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022 (GlobeNewswire)
Jan-06-23 08:00AM	Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications (Business Wire) +9.48%
Dec-28-22 04:00PM	Akoya to Participate at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-22 04:00PM	Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day (GlobeNewswire)
Dec-07-22 05:15AM	Institutions own 23% of Akoya Biosciences, Inc. (NASDAQ:AKYA) shares but private equity firms control 49% of the company (Simply Wall St.)
Nov-07-22 05:25PM	Akoya Biosciences (AKYA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.86%
04:05PM	Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance (GlobeNewswire)
04:05PM	Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy (GlobeNewswire)
Nov-03-22 08:05AM	Akoya to Participate at Three Upcoming Investor Conferences (GlobeNewswire) +5.86%
Oct-11-22 08:05AM	Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022 (GlobeNewswire)
06:34AM	Akoya Biosciences (NASDAQ:AKYA) investors are sitting on a loss of 10% if they invested a year ago (Simply Wall St.)
Oct-06-22 01:40PM	Stephen Initiates This Spatial Biology Player Citing Strong Competitive Position (Benzinga)
Aug-31-22 08:05AM	Akoya to Participate at Four Upcoming Investor Conferences (GlobeNewswire)
Aug-11-22 05:24PM	Small Caps Begin to Rebound: 10 Stocks to Buy Now (Insider Monkey)
Aug-09-22 12:00AM	Akoya Biosciences, Inc. (AKYA) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-08-22 05:55PM	Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance (GlobeNewswire)
Jul-27-22 08:05AM	Akoya to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Jul-12-22 08:05AM	Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022 (GlobeNewswire)
Jul-01-22 07:53AM	Little-Known Akoya Biosciences Appears to Have Found a Bottom (TheStreet.com)
Jun-29-22 07:21AM	What Kind Of Investors Own Most Of Akoya Biosciences, Inc. (NASDAQ:AKYA)? (Simply Wall St.)
Jun-28-22 08:05AM	Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivons Proprietary OncoSignature® Test into a Companion Diagnostic (GlobeNewswire)
Jun-16-22 08:41AM	Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains? (Zacks) -6.33%
Jun-03-22 06:11AM	Insiders in Akoya Biosciences, Inc. (NASDAQ:AKYA) are down 7.8% on their US$882k purchase despite recent gains (Simply Wall St.) -5.31%

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKelligon Brian	President and CEO	Mar 20 '24	Option Exercise	0.30	7,500	2,272	239,368	Mar 22 05:54 PM
McKelligon Brian	President and CEO	Mar 20 '24	Sale	4.97	7,500	37,243	231,868	Mar 22 05:54 PM
McKelligon Brian	President and CEO	Mar 13 '24	Sale	4.94	7,500	37,035	224,368	Mar 14 08:41 PM
McKelligon Brian	President and CEO	Dec 19 '23	Option Exercise	0.30	7,500	2,272	160,063	Dec 20 07:16 PM
McKelligon Brian	President and CEO	Dec 19 '23	Sale	4.48	7,500	33,566	152,563	Dec 20 07:16 PM
McKelligon Brian	President and CEO	Dec 12 '23	Option Exercise	0.30	7,500	2,272	160,063	Dec 14 04:24 PM
McKelligon Brian	President and CEO	Dec 12 '23	Sale	4.25	7,500	31,871	152,563	Dec 14 04:24 PM
McKelligon Brian	President and CEO	Nov 20 '23	Option Exercise	0.30	7,500	2,272	160,063	Nov 22 04:00 PM
McKelligon Brian	President and CEO	Nov 20 '23	Sale	4.39	7,500	32,901	152,563	Nov 22 04:00 PM
Pla Frederic	Chief Operating Officer	Sep 07 '23	Buy	4.60	20,000	92,014	20,000	Sep 11 04:00 PM
Raffin Thomas A.	Director	Jun 12 '23	Buy	5.00	2,020,000	10,100,000	15,937,535	Jun 12 06:15 PM
Winkler Matthew	Director	Jun 12 '23	Buy	5.00	203,388	1,016,940	984,513	Jun 12 06:16 PM
SHEPLER ROBERT G	Director	Jun 12 '23	Buy	5.00	120,000	600,000	369,592	Jun 12 06:16 PM
Ek John Frederick	CFO	Jun 12 '23	Buy	5.00	20,000	100,000	20,000	Jun 12 06:18 PM
Mendel Scott	Director	Jun 12 '23	Buy	5.00	20,000	100,000	28,500	Jun 12 06:17 PM
LAI GOLDMAN MYLA	Director	Jun 12 '23	Buy	5.00	20,000	100,000	20,000	Jun 12 06:18 PM
McKelligon Brian	President/CEO	Jun 06 '23	Option Exercise	0.30	5,000	1,515	157,563	Jun 06 09:45 PM
McKelligon Brian	President/CEO	Jun 06 '23	Sale	5.71	5,000	28,537	152,563	Jun 06 09:45 PM

Open in Screener

LUMO

Lumos Pharma Inc

May 10 • 04:00PM ET

2.90

Dollar change -0.12
Percentage change -3.97	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAC DFUS DFAT DCOR

Index	-	P/E	-	EPS (ttm)	-4.19	Insider Own	39.19%	Shs Outstand	8.10M	Perf Week	-2.03%
Market Cap	23.52M	Forward P/E	-	EPS next Y	-1.99	Insider Trans	-0.08%	Shs Float	4.93M	Perf Month	7.01%
Income	-34.03M	PEG	-	EPS next Q	-1.14	Inst Own	25.59%	Short Float	6.09%	Perf Quarter	-3.01%
Sales	2.05M	P/S	11.47	EPS this Y	34.26%	Inst Trans	7.82%	Short Ratio	11.23	Perf Half Y	-28.04%
Book/sh	3.37	P/B	0.86	EPS next Y	27.51%	ROA	-60.27%	Short Interest	0.30M	Perf Year	-15.20%
Cash/sh	4.45	P/C	0.65	EPS next 5Y	15.20%	ROE	-78.34%	52W Range	2.41 - 4.55	Perf YTD	-8.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.27%	ROI	-101.27%	52W High	-36.26%	Beta	0.71
Dividend TTM	-	Quick Ratio	5.69	Sales past 5Y	106.75%	Gross Margin	97.85%	52W Low	20.33%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	5.69	EPS Y/Y TTM	-12.62%	Oper. Margin	-1785.18%	RSI (14)	52.91	Volatility	6.17% 7.03%
Employees	33	Debt/Eq	0.24	Sales Y/Y TTM	34.67%	Profit Margin	-1659.39%	Recom	1.00	Target Price	22.50
Option/Short	No / Yes	LT Debt/Eq	0.23	EPS Q/Q	-17.01%	Payout	-	Rel Volume	1.23	Prev Close	3.02
Sales Surprise	-	EPS Surprise	-1.93%	Sales Q/Q	61.33%	Earnings	Mar 07 AMC	Avg Volume	26.73K	Price	2.90
SMA20	3.86%	SMA50	2.54%	SMA200	-6.45%	Trades		Volume	32,788	Change	-3.97%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-21	Upgrade	Stifel	Hold → Buy	$4 → $24
Dec-03-20	Initiated	Cantor Fitzgerald	Buy	$32
Aug-26-20	Initiated	Piper Sandler	Overweight	$26
Aug-17-20	Resumed	ROTH Capital	Buy	$51
Aug-04-20	Initiated	H.C. Wainwright	Buy	$33

May-09-24 02:51PM	Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 (GlobeNewswire)
Apr-18-24 04:05PM	Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings (GlobeNewswire)
Mar-20-24 08:00AM	Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 (GlobeNewswire) +7.33%
Mar-08-24 02:06PM	Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:54PM	LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:01PM	Loading…
04:01PM	Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update (GlobeNewswire)
Feb-26-24 09:00AM	Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024 (GlobeNewswire)
Feb-05-24 04:05PM	Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-04-24 04:05PM	Lumos Pharma Promotes Pisit Duke Pitukcheewanont, MD to Chief Medical Officer (GlobeNewswire)
Nov-21-23 04:15PM	Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency (GlobeNewswire)
Nov-20-23 04:05PM	Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November (GlobeNewswire)
Nov-07-23 04:35PM	Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates (GlobeNewswire)
04:01PM	Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints (GlobeNewswire)
Sep-26-23 09:00AM	Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting (GlobeNewswire)
Sep-14-23 08:00AM	Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting (GlobeNewswire)
04:34PM	Loading…
Sep-07-23 04:34PM	Lumos Pharma Announces Participation in Investor Conferences in September (GlobeNewswire)
Aug-22-23 09:00AM	Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape (GlobeNewswire) +7.61%
Aug-09-23 04:01PM	Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update (GlobeNewswire) -5.85%
Jul-26-23 09:00AM	Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023 (GlobeNewswire)
Jul-12-23 08:00AM	Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit (GlobeNewswire) +6.25%
Jun-28-23 04:01PM	Lumos Pharma Announces Departure of Chief Medical Officer (GlobeNewswire)
Jun-21-23 09:00AM	Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar (GlobeNewswire)
May-31-23 08:00AM	Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference (GlobeNewswire) -7.32%
May-25-23 08:00AM	Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st (GlobeNewswire)
May-22-23 09:00AM	Lumos Pharma to Participate in World Orphan Drug Congress USA (GlobeNewswire) +6.61%
May-08-23 08:00AM	Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES) (GlobeNewswire)
May-03-23 04:05PM	Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates (GlobeNewswire)
Apr-27-23 09:00AM	Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES) (GlobeNewswire)
Apr-19-23 09:00AM	Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 (GlobeNewswire) -5.83%
Mar-09-23 04:05PM	Lumos Pharma to Participate in Oppenheimers 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023 (GlobeNewswire)
02:00PM	Loading…
Mar-05-23 02:00PM	Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology (GlobeNewswire)
Mar-01-23 04:05PM	Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates (GlobeNewswire)
Feb-28-23 04:05PM	Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD (GlobeNewswire) +5.20%
Feb-15-23 04:05PM	Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023 (GlobeNewswire)
Jan-03-23 09:00AM	Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023 (GlobeNewswire) +8.03%
Dec-12-22 07:30AM	KOL Review of Lumos Pharmas Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients (GlobeNewswire) -15.75%
Nov-29-22 04:05PM	Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD (GlobeNewswire)
Nov-22-22 04:05PM	Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.85%
Nov-14-22 06:10AM	Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire) -34.68%
06:00AM	Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency (GlobeNewswire)
Sep-26-22 04:05PM	Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference (GlobeNewswire)
Aug-31-22 09:00AM	Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 07:30AM	Lumos Pharma Announces Share Repurchase Program (GlobeNewswire)
Aug-09-22 04:01PM	Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire) -5.26%
Jul-27-22 04:05PM	Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022 (GlobeNewswire)
Jul-24-22 08:27AM	Quite a few insiders invested in Lumos Pharma, Inc. (NASDAQ:LUMO) last year which is positive news for shareholders (Simply Wall St.)
Jul-20-22 08:32PM	Our long-term outlook for the stock market remains bullish: Here are 2 stocks that Oppenheimer likes (TipRanks)
May-16-22 04:05PM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 04:01PM	Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates (GlobeNewswire)
May-06-22 10:25AM	Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation (Simply Wall St.)
May-05-22 09:00AM	Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial (GlobeNewswire)
Apr-26-22 09:00AM	Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022 (GlobeNewswire) +7.50%
Apr-11-22 08:30AM	Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD (GlobeNewswire)
Mar-23-22 04:05PM	Lumos Pharma to Participate in the Cantor Rare Disease Symposium (GlobeNewswire)
Mar-10-22 04:01PM	Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials (GlobeNewswire)
09:00AM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-23-22 09:00AM	Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022 (GlobeNewswire)
Feb-14-22 12:05PM	Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year (Simply Wall St.)
Jan-05-22 09:00AM	Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +6.19%
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +6.03%
Nov-24-21 10:00AM	Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround (Zacks)
Nov-15-21 11:14AM	We're Hopeful That Lumos Pharma (NASDAQ:LUMO) Will Use Its Cash Wisely (Simply Wall St.)
Nov-10-21 05:06PM	Lumos Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-08-21 10:42AM	Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know (Zacks)
Nov-03-21 04:01PM	Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates (GlobeNewswire)
Oct-21-21 04:05PM	Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021 (GlobeNewswire)
Sep-02-21 08:00AM	Lumos Pharma to Participate in September Investor Conferences (GlobeNewswire)
Aug-16-21 09:58AM	Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year (Simply Wall St.)
Aug-05-21 08:00AM	Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Aug-03-21 08:00AM	Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer (GlobeNewswire) -9.04%
Aug-02-21 08:00AM	Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President (GlobeNewswire) +10.66%
Jul-26-21 04:18PM	Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board (GlobeNewswire)
Jul-22-21 08:00AM	Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021 (GlobeNewswire)
Jul-20-21 04:01PM	Lumos Pharma Announces Clinical Updates (GlobeNewswire)
Jun-28-21 08:00AM	Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment (GlobeNewswire)
May-19-21 09:00AM	Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-13-21 09:00AM	Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit (GlobeNewswire)
May-05-21 04:01PM	Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire) -7.41%
02:30PM	Lumos Pharma Inc to Host Earnings Call (ACCESSWIRE)
Apr-28-21 09:00AM	Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021 (GlobeNewswire)
Apr-27-21 08:00AM	Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar (GlobeNewswire)
Apr-20-21 04:05PM	Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession (GlobeNewswire)
Apr-14-21 04:05PM	Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency (GlobeNewswire) +5.78%
Mar-20-21 11:00AM	Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency (GlobeNewswire)
Mar-11-21 04:05PM	Lumos Pharma to Participate in March 2021 Investor Conferences (GlobeNewswire)
Mar-09-21 04:05PM	Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD (GlobeNewswire)
01:30PM	Lumos Pharma Inc to Host Earnings Call (ACCESSWIRE)
Mar-04-21 09:00AM	Data Supporting Use of Predictive Enrichment Markers for Lumos Pharmas LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society (GlobeNewswire) -5.82%
Mar-02-21 04:05PM	Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting (GlobeNewswire)
12:30PM	Will Lumos Pharma (LUMO) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-22-21 04:15PM	Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021 (GlobeNewswire) -5.92%
Feb-16-21 04:01PM	Lumos Pharma Announces Changes to its Board of Directors (GlobeNewswire)
Dec-18-20 09:00AM	Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference (GlobeNewswire)
Dec-16-20 02:19AM	What You Need To Know About Lumos Pharma, Inc.'s (NASDAQ:LUMO) Investor Composition (Simply Wall St.) +15.38%
Nov-30-20 05:35PM	Is Lumos Pharma (LUMO) A Good Stock To Buy Now? (Insider Monkey)
Nov-23-20 07:43PM	Lumos Pharma to Participate in December Investor Conferences (GlobeNewswire)
Nov-10-20 04:01PM	Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results (GlobeNewswire)

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKew John C.	Chief Scientific Officer	Apr 03 '24	Sale	2.77	2,214	6,144	17,153	Apr 03 05:10 PM
McKew John C.	Chief Scientific Officer	Feb 06 '24	Sale	3.03	438	1,328	18,403	Feb 07 05:22 PM
McKew John C.	Chief Scientific Officer	Aug 02 '23	Sale	3.21	3,407	10,919	18,707	Aug 03 04:58 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

AKYA

Akoya Biosciences Inc

LUMO

Lumos Pharma Inc

Upgrade your FINVIZ experience